UK universities launch 4D medical device manufacturing project
The 4D Health Tech initiative seeks to fill a crucial gap in traditional medical device manufacturing design processes by incorporating factors such as growth, movement, and tissue regeneration or degeneration, which are often overlooked.
The project will promote the use of materials that degrade predictably and promote faster healing, and combine this ethos with automated design, advanced manufacturing processes, and patient specific pre-clinical testing – which is expected to result in 'better' medical devices that cater to more diverse patient populations.
Backed by £1.2m in funding from the UK Research and Innovation's (UKRI) Engineering and Physical Sciences Research Council (EPSRC), the three-year project will create Network Plus, an initiative intended to connect academics, businesses, clinicians, patients, and policymakers, serving as a conduit towards the creation of bigger, longer-term research projects in the field.
The project funding is part of a broader £10m package allocated by EPSRC across the UK's manufacturing sector to respond to Tomorrow's Engineering Research Challenges, a paper the UKRI published in 2022. Concerning medical device and equipment manufacturing, the paper highlights the importance of a re-manufacturing and re-use approach to ensure sustainability in manufacturing for the sector to support a move towards the principles of a circular economy.
According to Dr Sophie Cox, associate professor in healthcare technologies at Birmingham University's School of Chemical Engineering, medical devices designed to replace or repair our bodies typically neglect the dimension of time, a reality that compromises their function and lifespan.
'Our vision is to transform the way we engineer medical devices,' said Dr Cox.
'Fostering connections across the supply chain will create a new culture of 4D Health Tech embedding innovative thinking, patient perspective and diversity – ensuring this new age of medical devices offers improved healthcare outcomes for everyone.'
In related manufacturing developments in the medical device sector, companies are ramping up their investment in 3D printing for the creation of custom prosthetics, implants and surgical tools that meet the individual needs of patients. According to GlobalData analysis, the medical 3D printing market is growing at a CAGR of 21% and forecast to reach a valuation of $4bn in 2026, up from $2bn in 2022.
"UK universities launch 4D medical device manufacturing project" was originally created and published by Medical Device Network, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Trade-offs abound as big pharma makes direct-to-consumer transition
Novo Nordisk is the latest drugmaker to slash the price of a blockbuster medicine via its online platform amid drug pricing reforms in the US, but analysis shows a smooth transition to direct-to-consumer (DTC) channels will be tricky. US President Donald Trump has made reducing drug prices in the country one of his administration's key targets. He has spearheaded this goal with the Most Favoured Nation (MFN) policy, a legislative framework that would tie US drug prices to the lowest prices in other developed countries. As part of this push, Trump has urged pharmaceutical companies to embrace DTC business models. This includes companies establishing their own platforms or opting in to those from third parties that cut out middlemen, meaning final drug prices are lower. GlobalData's senior pharma strategic intelligence analyst Wafaa Hassan comments: 'The [DTC] development, closely tied to the administration's 'America First' healthcare agenda and its revived MFN pricing framework, marks a renewed phase of pressure on drugmakers to lower domestic prices while signalling alignment between the White House and the pharmaceutical industry.' Earlier this year, Novo Nordisk unveiled its DTC platform NovoCare Pharmacy with a heavily discounted price for weight loss drug Wegovy (semaglutide). Just this week, the drugmaker added type 2 diabetes treatment Ozempic (semaglutide) to the platform. Both drugs are available to cash-paying patients for $499 each for a monthly supply. The list price of both drugs in the US sits at around $1,300 per month. While the move to discount the two drugs is more likely a response to the popularity of cheaper compounded alternatives, Trump will nevertheless be pleased with Novo's decision. Ozempic – a drug that generated global sales of $10bn in Q2 this year alone – being available for cheaper on a DTC platform is a coup Trump will likely point to in the face of criticism for his pricing reforms. However, challenges such as a limited patient awareness and disruption to traditional distribution channels could hinder the adoption of the DTC models by pharma companies, according to analysis by GlobalData. Hassan adds: 'From a drugmaker perspective, more challenges will occur following the initiatives, such as new operational demands, margin pressure and potential friction with insurers. The likelihood of success will only depend on how well the pharma industry navigates these trade-offs in the upcoming months.' Novo is far from the only big pharma company bolstering DTC medicine offerings. Novo's main rival in the GLP-1RA arena, Eli Lilly, has also conducted similar moves. The company began offering its weight loss medication Zepbound (tirzepatide) to self-paying patients at a steep discount on its own DTC platform LillyDirect in 2024. Taking a page from the two GLP-1RA developers, Bristol Myers Squibb (BMS) and Pfizer also established a DTC online programme for their blockbuster blood thinner Eliquis (apixaban) in July. BMS, Pfizer, Eli Lilly, and Novo Nordisk were among 17 pharma companies to receive a letter from Trump requesting more steps be taken by them to cut drug prices. "Trade-offs abound as big pharma makes direct-to-consumer transition" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Yahoo
Pfizer's sickle cell disease candidate fails Phase III trial
Pfizer is mulling its options after its investigational sickle cell disease drug failed to meet the primary endpoint in a Phase III trial. The THRIVE-131 study (NCT04935879) was evaluating inclacumab, an investigational P-selectin inhibitor, in patients 16 years of age and older with sickle cell disease. The trial failed to meet its primary endpoint of a significant reduction in the rate of vaso-occlusive crises (VOCs) after 48 weeks, placing the drug's future in jeopardy. Pfizer's chief inflammation and immunology officer Dr Michael Vincent, said: 'While the THRIVE-131 results did not meet our expectations, we remain committed to better understanding these results and sharing them with the medical and sickle cell community in the interest of advancing our collective understanding of sickle cell disease. We remain focused on our mission of bringing much-needed treatments to patients with sickle cell disease.' The therapy was generally well tolerated in THRIVE-131, with the most common adverse events (AEs) being anaemia, arthralgia, back pain, headache, malaria, sickle cell anaemia with crisis, and upper respiratory tract infection. Analyses of the data will be shared with the scientific and patient community in due course. The therapy is still being assessed in the THRIVE-133 OLE trial (NCT05348915) to evaluate the long-term safety of inclacumab. If approved, GlobalData predicts global sales of the drug to reach $267m in 2031. GlobalData is the parent company of Clinical Trials Arena. Pfizer's sickle cell disease woes This is the latest hit in sickle cell disease for Pfizer. In September 2024, it withdrew its therapy Oxbryta (voxelotor) in all approved markets after data suggested an imbalance in VOCs and fatal events. The company has reviewed and shared the data with the US Food and Drug Administration (FDA) and European Medicines Agency (EMA). The company is also awaiting the lifting of a partial clinical hold by the FDA on its Phase III trial of osivelotor, a haemoglobin S polymerisation inhibitor, in sickle cell disease. The FDA's order has paused enrolment into the trial, with Pfizer stating data will be shared as it becomes available. Approved therapies in the sickle disease treatment space are combating slow growth. Vertex and CRISPR Therapeutics' Casgevy (exagamglogene autotemcel) only reached revenue of $10m in 2024, with a $2.2m price tag per patient proving a barrier to initial uptake. Vertex said it expects the number of new patients initiating cell collection to grow significantly throughout 2025, with signals that this is already happening. GlobalData predicts Casgevy sales will increase significantly in 2025, with a forecast of $107m, with projections that the gene therapy will reach blockbuster status in 2030. The therapy gained approval by the National Institute for Health and Care Excellence (NICE) for use in sickle cell disease in January 2025, meaning it is now available for use on the UK's National Health Service (NHS). "Pfizer's sickle cell disease candidate fails Phase III trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 days ago
- Yahoo
Alpha Global to distribute LIO mental health operating platform
Healthcare solutions provider Alpha Global has entered an exclusive distribution agreement to introduce the LIO mental health operating platform in Australia. The platform employs a patented infrared system for contactless remote patient monitoring, enhancing the delivery of mental health services with its FDA-approved software. It tracks patients' sleep patterns and vital signs, offering valuable insights without disturbing the patient. Alpha Global product head Jeremy Clare said: "We're incredibly excited to bring the second generation of mental health monitoring technology to Australia with the launch of LIO. This platform is a significant step forward in supporting clinicians with intelligent, contactless insights that enhance patient care and safety. 'It's a proud moment for us to introduce a solution purpose-built for mental health environments, one that reflects our mission to connect healthcare professionals and carers with integrated technology that transforms patient outcomes." LIO's platform integrates ambient monitoring, digital observations, and management insights, streamlining operations for frontline teams and hospital leaders. With features such as adaptive monitoring modes, digital observations with smart scheduling, and advanced compliance reporting, LIO is set to enhance how care is delivered and managed. In addition to patient care benefits, the solution offers operational advantages for hospital leaders, promoting consistent care that meets regulatory standards. The platform's integration with electronic patient records (EPR) systems minimises duplication and streamlines documentation processes. In addition, the new ambient monitoring unit promises faster and easier installation, typically completed within one to two weeks, minimising disruptions to hospital operations. LIO CEO Todd Haedrich said: "LIO is a fully integrated, whole-hospital solution, purpose-built for the complex realities of inpatient mental health, with powerful capabilities that help providers deliver consistently high standards of compassionate, patient-centred care. 'We're fortunate to partner with such a credible and respected organisation in Australia to ensure providers and patients have access to this much-needed technology." "Alpha Global to distribute LIO mental health operating platform" was originally created and published by Hospital Management, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
